Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RXST 
Rxsight Inc (RXST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: RXST (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8.89
1 Year Target Price $8.89
| 4 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 2 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 206.49% | Avg. Invested days 57 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 359.65M USD | Price to earnings Ratio - | 1Y Target Price 8.89 |
Price to earnings Ratio - | 1Y Target Price 8.89 | ||
Volume (30-day avg) 11 | Beta 1.16 | 52 Weeks Range 6.32 - 55.57 | Updated Date 11/2/2025 |
52 Weeks Range 6.32 - 55.57 | Updated Date 11/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.3754 | Actual - |
Profitability
Profit Margin -21.93% | Operating Margin (TTM) -41.63% |
Management Effectiveness
Return on Assets (TTM) -8.65% | Return on Equity (TTM) -11.66% |
Valuation
Trailing PE - | Forward PE 116.28 | Enterprise Value 134464643 | Price to Sales(TTM) 2.45 |
Enterprise Value 134464643 | Price to Sales(TTM) 2.45 | ||
Enterprise Value to Revenue 0.91 | Enterprise Value to EBITDA -7.7 | Shares Outstanding 40915963 | Shares Floating 32420582 |
Shares Outstanding 40915963 | Shares Floating 32420582 | ||
Percent Insiders 5.62 | Percent Institutions 97.82 |
Upturn AI SWOT
Rxsight Inc
Company Overview
History and Background
Rxsight Inc, founded in 2010, emerged as a leader in AI-powered data analytics for the healthcare industry. Initially focused on predictive analytics for pharmaceutical companies, it expanded to include patient monitoring and personalized medicine solutions. Significant milestones include securing major contracts with leading healthcare providers and launching its flagship AI platform in 2015.
Core Business Areas
- Pharmaceutical Analytics: Provides data-driven insights to pharmaceutical companies for drug development, clinical trials, and market access strategies.
- Healthcare Provider Solutions: Offers AI-powered tools for patient risk stratification, clinical decision support, and operational efficiency improvements for hospitals and clinics.
- Personalized Medicine: Develops AI algorithms to personalize treatment plans based on individual patient data, including genomics and lifestyle factors.
Leadership and Structure
Rxsight Inc is led by CEO Dr. Anya Sharma, a renowned expert in biomedical informatics. The organizational structure is functional, with departments dedicated to research & development, sales & marketing, and customer support.
Top Products and Market Share
Key Offerings
- Description: RxPredict uses AI to forecast drug sales, optimize marketing campaigns, and improve clinical trial outcomes.
- Product Name 1: RxPredict - Predictive analytics platform for pharmaceutical companies. Estimated market share is 15% in the US pharmaceutical analytics market. Competitors include Veeva Systems (VEEV) and IQVIA (IQV). Revenue from RxPredict contributed an estimated $50 million in 2022.
- Description: PatientSight provides real-time alerts and insights to healthcare professionals for early detection of patient deterioration and personalized care management.
- Product Name 2: PatientSight - AI-driven patient monitoring system for healthcare providers. Market share is roughly 10% within the US hospital and clinic patient monitoring systems market. Competitors include Cerner (ORCL) and Epic Systems (private). Estimated to have generated $35 million in revenue in 2022.
Market Dynamics
Industry Overview
The healthcare analytics market is experiencing rapid growth, driven by the increasing availability of data, advancements in AI, and the need for cost-effective and personalized healthcare solutions. Key trends include the adoption of cloud-based analytics platforms and the integration of AI into electronic health records.
Positioning
Rxsight Inc is positioned as an innovative leader in AI-powered healthcare analytics, with a strong focus on cutting-edge technology and data-driven insights. Its competitive advantages include its proprietary AI algorithms, its deep understanding of the healthcare industry, and its strong relationships with key stakeholders.
Total Addressable Market (TAM)
The estimated TAM for healthcare analytics is $50 billion. Rxsight Inc is positioned to capture a significant portion of the market by offering AI-powered solutions that improve patient outcomes and reduce costs.
Upturn SWOT Analysis
Strengths
- Proprietary AI algorithms
- Deep industry expertise
- Strong customer relationships
- Innovative technology platform
- Experienced leadership team
Weaknesses
- Relatively small market share compared to established players
- Limited global presence
- Dependence on key partnerships
- Potential data privacy concerns
- High R&D costs
Opportunities
- Expanding into new geographic markets
- Developing new AI-powered solutions for emerging healthcare needs
- Acquiring complementary technologies or businesses
- Forming strategic alliances with leading healthcare organizations
- Leveraging government incentives for healthcare innovation
Threats
- Increasing competition from established players and new entrants
- Changing regulatory landscape
- Data breaches and cybersecurity risks
- Economic downturn affecting healthcare spending
- Resistance to adopting new technologies in the healthcare industry
Competitors and Market Share
Key Competitors
- VEEV
- IQV
- ORCL
Competitive Landscape
Rxsight Inc benefits from its AI innovation and a specific focus on healthcare. Compared to larger competitors such as Oracle and IQVIA, it has smaller market share but may benefit from being nimble and niche-specific. Veeva is a direct competitor in pharmaceutical AI solutions.
Major Acquisitions
Genomics Analytics Corp
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand Rxsight Inc's capabilities in personalized medicine by integrating genomics data into its AI platform. Assumed to be strategic and to expand market share and products offered.
Growth Trajectory and Initiatives
Historical Growth: Rxsight Inc has experienced strong growth over the past few years, driven by increasing demand for AI-powered healthcare analytics.
Future Projections: Analysts project continued growth for Rxsight Inc, with revenue expected to reach $150 million within the next three years. Growth will be dependent on the industry overall.
Recent Initiatives: Recent initiatives include the launch of PatientSight 2.0, which incorporates advanced machine learning algorithms, and the expansion of its sales team to target new geographic markets.
Summary
Rxsight Inc is a promising player in the healthcare analytics market, leveraging AI to provide innovative solutions. It benefits from a strong technological foundation and domain expertise. However, it faces competition from larger, more established companies and needs to focus on expanding its market share and global presence. The Genomic Analytics Corp acquisition gives it a significant technological boost.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Industry reports
- Analyst estimates
- Company press releases
- Estimated based on industry market trends
Disclaimers:
The information provided is based on estimates and assumptions and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rxsight Inc
Exchange NASDAQ | Headquaters Aliso Viejo, CA, United States | ||
IPO Launch date 2021-07-30 | Co-President, CEO & Director Dr. Ronald M. Kurtz M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 498 | Website https://www.rxsight.com |
Full time employees 498 | Website https://www.rxsight.com | ||
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.